ImmuCell Corporation

ICCC ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $-168.1K $508.4K $1.2M $-167.2K $117.4K $89.5K $-409.5K $-384.7K
Depreciation & Amortization
Depreciation $885.3K $783.3K $525.9K $446.0K $414.3K $399.6K $413.1K $416.9K
Amortization $19.1K $19.1K
Stock-Based Compensation $199.8K $67.4K $23.2K $30.0K $31.4K $36.0K $38.2K $29.5K
Net Cash from Operating Activities $1.2M $-222.3K $2.9M $302.4K $1.1M $344.4K $-37.3K $-808.6K
Investing Activities
Capital Expenditures $17.8M $3.6M $2.7M $1.5M $597.7K $275.4K $243.7K $116.5K
Business Acquisitions $532.0K
Net Cash from Investing Activities $-12.3M $-4.5M $-4.6M $-1.5M $-1.3M $1.7M $-1.2M $266.5K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $9.7M $8.3M $2.4M $-187.2K $-159.3K $-114.8K $614.6K $965.7K
Net Change in Cash $-1.4M $3.6M $723.3K $-1.4M $-403.3K $1.9M $-617.5K $423.5K
Free Cash Flow $-16.6M $-3.8M $181.0K $-1.2M $501.0K $69.0K $-281.1K $-925.2K
← Newer Page 2 of 3 Older →